Program
Insulin Aspart
Also written as “insulin aspart”, “biphasic insulin aspart” and “Faster-acting insulin aspart”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Diabetes, Gestational, led by 9 companies.
Drug pageInsulin Aspart: every studyMany companies study it; this page follows only the 139 they lead. All 207 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 1280 open or running | phase 4since Nov 4, 2004 | Jul 17, 2003 | none ahead |
| Amphastar Pharmaceuticalsits history only | 20 open or running | phase 3since Sep 12, 2022 | Sep 12, 2022 | none ahead |
| Geropharmits history only | 20 open or running | phase 3since Sep 3, 2019 | Sep 3, 2019 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 1since Aug 8, 2007 | Aug 8, 2007 | none ahead |
| CeQurits history only | 10 open or running | no phasesince Mar 24, 2015 | Mar 24, 2015 | none ahead |
| Defymedits history only | 11 open or running | no phasesince Dec 3, 2021 | Dec 3, 2021 | Dec 2026NCT05221359 |
| Sunshine Lake Pharmaits history only | 10 open or running | phase 3since Mar 6, 2023 | Mar 6, 2023 | none ahead |
| The United Laboratories Internationalits history only | 10 open or running | no phasesince May 6, 2026 | May 6, 2026 | none ahead |
| Tonghua Dongbao Pharmaceutical | 10 open or running | phase 3since Jun 5, 2015 | Jun 5, 2015 | none ahead |
Also a collaborator on its studies: Mylan and Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tonghua Dongbao Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 5, 2015First study: phase 3 study in Diabetes MellitusFirst studyNCT02491528 · 563 enrolled · China
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The one study Tonghua Dongbao Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02491528Diabetes Mellitus · China | 3 | Completed | Aug 12, 2016 | 563 |
How it is read
Names in the registry
- “insulin aspart”, 60 entries
- “biphasic insulin aspart”, 27 entries
- “Faster-acting insulin aspart”, 24 entries
- “biphasic insulin aspart 50”, 13 entries
- “biphasic insulin aspart 70”, 12 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 57 studies
- Diabetes Mellitus, Type 1, 54 studies
- Diabetes Mellitus, 28 studies
- Diabetes, Gestational, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.